1 The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China A 42 year-old ...

Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Introduction: The autoantibody-driven disease pemphigus vulgaris (PV) impairs desmosome adhesion in the epidermis. In desmosomes, the pemphigus autoantigens desmoglein 1 (Dsg1) and Dsg3 link adjacent ...